DYRK1A, a dual specificity kinase expressed during early neurogenesis that has been a target in pilot studies for treatment of cognitive deficits in DS (De la Torre et al. 2014; de la Torre et al. 2016), also produced no phenotype. This evidence concerns the gene DYRK1A and Dravet syndrome.